Brief: Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration
22/07/2026 22:51
BRIEF-Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration July 22 (Reuters) - Arcus Biosciences Inc RCUS.N:
ARCUS BIOSCIENCES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL TRIAL COLLABORATION TO EVALUATE CASDATIFAN COMBINED WITH IVONESCIMAB IN KIDNEY CANCER
ARCUS BIOSCIENCES INC: UNDER TERMS OF AGREEMENT, SUMMIT WILL SUPPLY IVONESCIMAB AND ARCUS WILL CONDUCT AND SPONSOR COMBINATION STUDY
ARCUS BIOSCIENCES INC: BOTH COS WILL CONTRIBUTE TO COST OF STUDY, EACH CO WILL RETAIN DEVELOPMENT & COMMERCIAL RIGHTS TO THEIR RESPECTIVE MOLECULES
ARCUS BIOSCIENCES INC: INITIAL DATA FROM THIS CLINICAL TRIAL COLLABORATION IS EXPECTED TO BE GENERATED BY MID-2027
Source text: ID:nBw5cyfqKa
Further company coverage: RCUS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering